Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01718990 · ClinicalTrials.gov registry record
Biomarker Discovery for Novel Drug Development in Idiopathic Pulmonary Fibrosis
A clinical trial, sponsored by University of California, San Francisco.
- Completed
- Registry status
- 110
- Enrollment target
NCT01718990 is a clinical trial that has completed, run by University of California, San Francisco. The registered enrollment target is 110 participants.
The verdict
NCT01718990 has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- 110 participants
- Enrollment target
Study Summary
Drug discovery can take many years especially since most studies to measure effectiveness depend on clinical outcomes like pulmonary function tests and hospitalizations. This is an observational study designed to collect information, blood, and bronchoalveolar lavage fluid in people who have IPF and those who do not. The people who have IPF will be followed for 12 months to collect more biological samples and record clinically relevant information. The goal of this study is to identify new molecular markers that are measurable and reliable in people who have IPF. It is hoped that these markers can be used in future drug studies to significantly speed up the process of finding drugs that help.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 110 participants |
| Start Date | 2012-10 |
| Est. Completion | 2018-12-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01718990
The ClinicalTrials.gov registry entry for NCT01718990 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 110 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT01718990 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01718990 about?
NCT01718990 is a clinical study titled "Biomarker Discovery for Novel Drug Development in Idiopathic Pulmonary Fibrosis". Drug discovery can take many years especially since most studies to measure effectiveness depend on clinical outcomes like pulmonary function tests and hospitalizations. This is an observational study designed to collect information, blood, and bronchoalveolar lavage fluid in people who have IPF an...
What is the current status of trial NCT01718990?
This trial is currently completed. The enrollment target is 110 participants. The study started on 2012-10. Estimated completion is 2018-12-31.
Who is sponsoring clinical trial NCT01718990?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.